Publicaciones en las que colabora con Renée Ribacoba Montero (37)

2019

  1. HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease

    Neurobiology of Aging, Vol. 76, pp. 215.e9-215.e14

2017

  1. Correlación de funciones ejecutivas con la lateralidad de la afectación del circuito nigro-estriatal en la enfermedad de parkinson

    Libro de capítulos III Congreso Nacional de Psicología (Consejo General de la Psicología de España), pp. 45-49

  2. Epilepsia mioclónica en el síndrome de Down y en la enfermedad de Alzheimer

    Neurologia, Vol. 32, Núm. 2, pp. 69-73

2016

  1. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression

    BMC Neurology, Vol. 16, Núm. 1

2014

  1. Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms

    Neuroscience Letters, Vol. 562, pp. 45-49

  2. MiRNA Profile in the Substantia Nigra of Parkinson’s Disease and Healthy Subjects

    Journal of Molecular Neuroscience, Vol. 54, Núm. 4, pp. 830-836

  3. The screening of the 3′UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease

    Journal of Human Genetics, Vol. 59, Núm. 6, pp. 346-348

2013

  1. Mutational screening of PARKIN identified a 3′ UTR variant (rs62637702) associated with parkinson's disease

    Journal of Molecular Neuroscience, Vol. 50, Núm. 2, pp. 264-269

  2. Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls

    Journal of Neurology

2012

  1. A search for SNCA 3′ UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease

    Journal of Molecular Neuroscience, Vol. 47, Núm. 3, pp. 425-430

2011

  1. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease

    Movement Disorders, Vol. 26, Núm. 5, pp. 819-823

  2. Vasomotor Reactivity Is Similarly Impaired in Patients with Alzheimer's Disease and Patients with Amyloid Hemorrhage

    Journal of Neuroimaging, Vol. 21, Núm. 2

2010

  1. Analysis of the micro-RNA-133 and PITX3 genes in Parkinson's disease

    American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 153, Núm. 6, pp. 1234-1239

  2. Cognitive impairment in Parkinson's disease without dementia

    Movement Disorders, Vol. 25, Núm. 13, pp. 2136-2141

  3. FGF20 rs12720208 SNP and microRNA-433 variation: No association with Parkinson's disease in Spanish patients

    Neuroscience Letters, Vol. 479, Núm. 1, pp. 22-25

  4. Mutational spectrum of the SPG4 (SPAST) and SPG3A (ATL1) genes in Spanish patients with hereditary spastic paraplegia

    BMC Neurology, Vol. 10

  5. Partial motor status epilepticus as a clinical manifestation of carotid stenosis

    International Archives of Medicine, Vol. 3, Núm. 1

2009

  1. Action naming is impaired in Parkinson disease patients

    Neuropsychologia, Vol. 47, Núm. 14, pp. 3271-3274

  2. Mutational screening of the Mitochondrial transcription factors B1 and B2 (TFB1M and TFB2M) in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 15, Núm. 6, pp. 468-470

  3. Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease

    Journal of Neural Transmission, Vol. 116, Núm. 10, pp. 1289-1293